Headquartered in Waltham, MA, EyePoint is a publicly-traded, pharmaceutical company focused on ophthalmology. EW’s investment enabled EyePoint’s acquisition of a recently-approved product, DEXYCU, a steroidal injection following cataract surgery that can replace the burdensome steroidal drops used as the standard of care today. EyePoint also received FDA approval for its pipeline product YUTIQ, a three-year posterior uveitis implant, in October 2018.
“I am so pleased with our working relationship and the experience, guidance and support that EW provides to EyePoint Pharmaceuticals. The quality of their input, at both the Board level and the management level, has been superb and we have forged a true partnership.”
CEO, EyePoint Pharmaceuticals
Testimonials and endorsements reflect portfolio company management’s opinions and beliefs regarding the company and the investment. Such opinions and beliefs are subjective, do not represent a complete assessment of the company, the market or EW’s overall investment performance and cannot be independently verified. Such statements are being offered as references for purposes of demonstrating the benefits of working with the EW team and not for the purpose of soliciting investors. Portfolio company executives receive/received a salary and economics from the portfolio company. No executives were paid for their testimonial or endorsement. There is a conflict of interest in these unpaid testimonials and endorsements in that all speakers stand to benefit from EW’s success and they work/worked for an EW portfolio company.